Fiona C. Baker, PhD

Stephanie Faubion, MD, and Fiona Baker, PhD, discuss how elinzanetant can play a role in sleep disturbances because of VMS, emerging data on the subject, and how to determine the right candidate for the NK1-3 dual-receptor antagonist.

Fiona C. Baker, PhD, explains how menopausal sleep disturbance differs from other forms of sleep disruption, citing the role of vasomotor symptoms, hormone changes, and an increased postmenopausal risk of sleep apnea in driving nighttime awakenings.

In part 2 of our discussion with Fiona Baker, PhD, she details how to interpret data from the NIRVANA study, which revealed reductions in wakefulness after sleep onset in the elinzanetant group vs placebo.

Presented at SLEEP 2026, NIRVANA data show a consistent elinzanetant treatment signal across three sleep measurement modalities, extending earlier OASIS trial findings on patient-reported sleep outcomes in menopausal women.

Fiona C. Baker, PhD, summarizes the most clinically relevant takeaways from NIRVANA and explores how these findings may shape future treatment decisions and guideline conversations.

Fiona C. Baker, PhD, discusses the interconnected nature of VMS and sleep disturbances, stressing why treating both together—and achieving rapid symptom relief—is key for patient satisfaction.

Fiona C. Baker, PhD, compares elinzanetant with current therapeutic options, noting how its profile aligns with the needs of patients experiencing both VMS and sleep disturbances.

Fiona C. Baker, PhD, emphasizes the importance of patient-reported outcomes in assessing elinzanetant’s overall benefit, including insights on symptom recurrence and quality-of-life improvements.

Fiona C. Baker, PhD, reviews NIRVANA’s findings showing early onset of relief for both VMS and sleep disturbances, supported by patient-reported improvements in sleep quality, duration, and nighttime awakenings.

Fiona C. Baker, PhD, outlines the NIRVANA study’s design and goals, noting its focus on evaluating elinzanetant’s impact on vasomotor symptoms and sleep-related outcomes.